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Summary. — Nanomedicines are submicrometer-sized carrier materials designed
to improve the biodistribution of systemically administered (chemo)therapeutic
agents. By delivering pharmacologically active agents more effectively and more
selectively to the pathological site nanomedicines aim to improve the balance be-
tween the efficacy and the toxicity of systemic (chemo)therapeutic administrations.
Nanomedicine formulations have also been used for imaging applications and, in
recent years, for theranostic approaches, that is, for systems and strategies in which
disease diagnosis and therapy are combined. On the one hand, “classical” drug
delivery systems are being co-loaded with both drugs and contrast agents. Actu-
ally, nanomaterials with an intrinsic ability to be used for imaging purposes, such as
iron-oxide–based magnetic nanoparticles (MNPs), are increasingly being loaded with
drugs or alone for combining disease diagnosis and therapy. In this study, non-ionic
surfactant vesicles loaded with lipophilic and hydrophilic MNPs have been prepared.
Vesicles have been characterized in terms of dimensions, ζ-potential, time stability,
bilayer characteristics and overall iron content. The encouraging obtained results
confirm that Tween 20 and Span 20 vesicles could be promising carriers for the de-
livery of hydrophilic and lipophilic MNPs, respectively, thereby prompting various
opportunities for the development of suitable theranostic strategies. The analyzed
formulations confirm the importance of surfactant chemical-physical characteristics
in entrapping the MNPs of different polarity, highlighting the high versatility of
niosomal bilayer and structure; property that make them so appealing among drug
delivery nanocarriers.
PACS 81.07.-b – Nanoscale materials and structures: fabrication and characteri-
zation.
PACS 82.70.Uv – Surfactants, micellar solutions, vesicles, lamellae, amphiphilic
systems, (hydrophilic and hydrophobic interactions).
PACS 61.46.Df – Structure of nanocrystals and nanoparticles.
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1. – Introduction
The use of nanoparticulate pharmaceutical carriers to enhance the in vivo efficiency of
many drugs well established itself over the past decade both in pharmaceutical research
and clinical setting. Surface modification of pharmaceutical nanocarriers, such as solid
lipid particles, polymeric nanoparticles, nanocapsules, liposomes, niosomes, micelles and
others [1,2] is normally used to control and modulate biological properties in a desirable
fashion and make them to simultaneously perform various therapeutically or diagnos-
tically important functions. The most important results of such modification allow an
increased stability and half-life of nanocarriers in the circulation, a better biodistribu-
tion, passive or active targeting into the required pathological zone. Furthermore, surface
modification can enable to obtain responsiveness to local physiological stimuli such as
pathology-associated changes in local pH and/or temperature, and ability to serve as
imaging/contrast agents for various imaging modalities (gamma-scintigraphy, magnetic
resonance imaging, computed tomography, ultrasonography). Nanoparticle formulations
have demonstrated clinical relevance by increasing drug efficacy and decreasing toxic-
ity and numerous targeted formulations are under clinical evaluation. There are unique
opportunities to use multifunctional formulations for both diagnostic and targeting pur-
poses [3]. Vesicles formed by surfactants are known as Niosomes or non-ionic surfactant
vesicles (NSVs). The self-assembly of non-ionic surfactants into vesicles was firstly re-
ported in the seventies by researchers in the field of cosmetics [4]. Niosomes are analogous
to liposomes; in fact the NSVs can be prepared following the same procedures, under a
variety of conditions, leading to the formation of unilamellar or multilamellar vesicular
structures [5]. When compared to phospholipid-based vesicles, the surfactant vesicles
have several advantages such as greater stability, thus lesser care in handling and storage
and lower cost, attractive for industrial applications both in the field of pharmaceutics
and cosmetics [5-9]. Moreover niosomes, like liposomes, are capable of encapsulating
both hydrophilic and lipophilic drugs [10]. The superior magnetic properties of iron ox-
ide magnetic nanoparticles (MNPs) along with their non-toxicity, biodegradability and
inexpensiveness, have made them a material of choice in many bioapplications, such
as contrast probes in magnetic resonance imaging (MRI). In order to confer colloidal
suspendability to the particles, additives, typically hydrophilic polymers are added dur-
ing the particle formation process, which passivate the nanocrystal surface and protect
against particle aggregation [11]. In this study, the preparation and characterization of
MNPs loaded niosomes that offer the opportunity for targeted, non-invasive diagnosis by
MRI will be described. For this purpose, iron oxide MNPs have been encapsulated into
surfactant vesicles to develop niosomal contrast agents, i.e., magnetic niosomes (MNs).
Here, we have focused our attention on iron oxide NPs with a hydrodynamic diameter
of 50 nm or less. Such MNPs consist of a magnetic core coated by various materials
(hydrophilic coating, e.g., dextran, or lipophilic coating, e.g., lipid or polymaleic acid
co-olefin) to improve the solubility and/or stability of the MNPs in colloidal suspension.
This particular feature makes MNs suitable as MRI contrast agents for several biomedical
applications and at the same time for active targeting strategies and for hyperthermia
based treatments. However, for in vivo applications, the circulation time of MNs in the
bloodstream should be long enough to ameliorate target-ligand interaction. This goal
can be achieved by steric stabilization of the niosomes (e.g., by adding a poly-ethylene
glycol [PEG]-based surfactant to the formulation). Tween 20 is a natural pegylated hy-
drophilic surfactant (HLB=16.7), it possesses 20 PEG units in its molecule and is able to
prevent the rapid recognition and consequent uptake of MNs via the mononuclear phago-
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Table I. – Samples composition. The MNPs in samples A1 and B1 were supplied by Colorobbia,
while those in sample A2 by Chemicell.
Sample Tw20 (mM) Sp20 (mM) Chol (mM) hMNPs (mg/mL) lMNPs (mg/mL)
A0 15 – 15 – –
A1 15 – 15 3.58 –
A2 15 – 15 3.58 –
B0 – 15 15 – –
B1 – 15 15 – 3.58
cyte system. Tween 20 could be an useful surfactant to prepare vesicles, as previously
reported [12-15] able to entrap hydrophilic MNPs. To entrap lipophilic MNPs, Span 20,
a lipophilic surfactant (HLB=8.6) without PEG units in its molecule have been used to
prepare MNPs loaded vesicles. The prepared vesicular formulations have been analyzed
in terms of chemical and physical characteristics, including iron oxide loading capacity,
encapsulation efficiency, particle size, ζ-potential, time stability, and the influence of the
magnetic cores on surfactant membrane polarity and microviscosity.
2. – Materials and methods
2.1. Materials. – Tween 20 (Tw20), Span 20 (Sp20), cholesterol (Chol), Sephadex
G75, Hepes salt {N-(2-idroxyethyl) piperazine-N-(2-ethanesulfonicacid)} and pyrene
were Sigma-Aldrich products (Sigma-Aldrich SRL, Milan, Italy). Hydrophilic magnetic
nanoparticles (hMNPs) (fluidMAG-CMX) were Chemicell products (Chemicell, Berlin,
Germany). Other kind of hMNPs and lipophilic magnetic nanoparticles (lMNPs) were a
kind gift of Ce.Ri.Col. (Colorobbia, Vinci, Italy). All other chemicals used throughout
this investigation were of analytical grade and no additional purification was carried out.
Double-distilled water was used throughout the study.
2.2. Vesicle preparation and purification. – Unilamellar vesicles were obtained from a
non-ionic surfactant/MNPs aqueous dispersion (Hepes pH 7.4) by means of the “film”
method as previously reported [5,16], according to the compositions in table I. Tw20 and
Sp20 concentration in the samples was always remarkably above their CMC (in water
at 25 ◦C: Tween 20 = 0.006 g/dL; Span 20 = not detectable). For this purpose, Tw20
or Sp20, Chol, lMNPs and pyrene (4mM in niosomes dispersion), when necessary, were
dissolved in a CHCl3/CH3OH (3:1) mixture in a round bottomed flask. After evaporation
of the solvents, the dried film containing lMNPS and/or pyrene was hydrated by addition
of 5mL (0.01M) Hepes pH 7.4 solution while in the case of dried film without lMNPs
and/or pyrene by addition of 5mL of hMNPs in Hepes buffer (0.01M) at pH 7.4. The
dispersion was vortexed for about 5 min and then sonicated for 5min at 60 ◦C using
a tapered microtip operating at 20 kHz at an amplitude of 16% (Vibracell-VCX 400-
Sonics, USA). In order to separate MNPs-loaded vesicles from untrapped substances,
for the evaluation of entrapment efficiency (e.e.), the vesicle dispersion was purified by
gel-filtration on Sephadex G75 (glass column 50× 1.2 cm), using Hepes buffer as eluent
in the case of MNs prepared with hMNPs from Chemicell, while for MNs with lMNPs
and hMNPs obtained by Ce.Ri.Col., the untrapped material was eliminated by filtration
with 1.2μm filter and then dialysis method.
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2.3. Light scattering measurements. – Dynamic light scattering (DLS) was used to
determine mean size and size distribution of non-ionic surfactant vesicles and to control
lMNPs and hMNPs dimensions. The vesicle dispersions were diluted 100 times with the
same buffer used for their preparation to avoid multiscattering phenomena. Buffer solu-
tions used for dynamic light scattering experiments were filtered through 0.45μm cellulose
filters to eliminate dust particles. Vesicle mean size and size distribution (polydispersity
index, PDI) were measured at 25 ◦C using a Malvern Nano ZS90 light scattering appara-
tus (Malvern Instruments Ltd., Worcestershire, UK) at a scattering angle of 90.0◦. The
same apparatus was used for the evaluation of ζ-potential of vesicles and of MNPs, which
were appropriately diluted (1:10) in distilled water at 25 ◦C. The laser Doppler anemom-
etry was used and hence the electrophoretic mobility of non-ionic surfactant vesicles was
measured. The ζ-potential value was calculated from the electrophoretic mobility in the
Smoluchowsky approximation. Reported data represent mean of the ζ-potential and of
the hydrodynamic diameter (dh) for the surfactant vesicles. Results of DLS experiments
are given as the average values obtained using samples from three different batches ±
standard deviation (SD).
2.4. Vesicle physical stability . – Physical stability studies of MNPs loaded vesicles
were carried out to investigate if significant changes of dh and ζ-potential of surfactant
vesicle dispersion occur during storage. For colloidal stability at different temperatures,
the vesicle formulations were stored at 4 ◦C and 25 ◦C for a period of 90 days. Samples
from each batch were withdrawn at definite time intervals (1, 30, 60 and 90 days) and
the ζ-potential and dh of vesicles were determined.
2.5. Determination of Iron entrapment efficiency (e.e.). – Fe e.e. within non-ionic
surfactant vesicles was determined using inductively coupled plasma mass spectrometry
(ICP-MS) on purified MNs. Samples were transferred into TFM vessels and digested by
means of a microwave oven (Ethos, Milestone, FKV, Sorisole, Bergamo, Italy) equipped
with a probe for the temperature control. The digestion mixture was constituted of 2mL
of H2O ultrapure (up), 4ml of HNO3 65% (v/v) (Merck, Darmstadt, Germany), 0.5mL
of HCl and 1mL of H2O2 40% (v/v) (Merck, Darmstadt, Germany). The digestion
programme was preceded by a soft pre-digestion treatment of the samples in order to
avoid any strong reaction during the final dissolution process. After cooling, the digested
solutions were quantitatively transferred in 50mL Falcon tubes by adding high purity
deionized water up to 20mL. These solutions were further diluted (1 + 9) before the
instrumental analysis. Measurements were performed by means of a dynamic reaction
cell (DRC) ICP-MS (Elan DCR II, Perkin Elmer SCIEX, Norwalk, CT, USA) operating
in DRC mode with ammonia as reaction gas (purity of 99.999%) so as to overcome the
likely interferences on the Fe determination. The cell parameters were the following: gas
flow = 0.6mL/min and RPq = 0.6. 56Fe was the isotope used for quantification purpose
with external calibration approach. Fe e.e. was calculated as the ratio between the mass
of the incorporated Fe and that of the Fe used for vesicle preparation. Magnetite content
in hMNPS Chemicell is 87% (w/w) of the total mass, while in hMNPs and lMNPS
Cericol the Fe content is 0.0496M and 0.0190M of the starting suspension. Results are
the average of three different batches ± SD.
2.6. Measurements of vesicular micropolarity . – The fluorescence experiments on vesi-
cles incorporating pyrene were carried out (Perkin-Elmer LS55 spectrofluorometer with
excitation wavelength 319 nm) to evaluate the micropolarity of the hydrocarbon bilayer
in vesicles. Pyrene allows the investigation of the lateral distribution and the dynamics
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Table II. – Samples characterization. The hydrodynamic diameter (dh), polydispersity index
(PDI), ζ-potential and Fe entrapment efficiency (e.e.) are reported.
Sample dh (nm) PDI ζ-potential (mV) e.e. (%)
A0 197.0± 5.1 0.304 −13.7± 0.8 0
A1 185.1± 9.4 0.244 −11.7± 0.4 53± 2
A2 211.2± 5.5 0.371 −26.2± 0.4 55.8± 2.3
B0 170.2± 2.0 0.192 −37.8± 0.5 0
B1 187.6± 2.8 0.131 −31.1± 1.0 15± 3
of membrane compounds. Pyrene in the bilayer is present as excimers at high con-
centrations; when the excimer fluorescence decrease, there is an increase in monomer
fluorescence. The monomer and the excimer have different fluorescent signals and the
ratio of the fluorescence intensities is directly related to the probe distribution in the
lipid network. The pyrene monomer fluorescent spectrum consists of five peaks. It is
well established that the ratio I1/I3 between the intensities of the first (I1) and third
(I3) vibration bands of the pyrene fluorescence spectrum (corresponding to 372 nm and
382 nm, respectively) is related to the polarity of the pyrene environment [17]. Low val-
ues of the I1/I3 ratio correspond to a non-polar environment. This ratio increases as
the polarity of the medium rises [17]. Since pyrene is solubilized inside the hydrocarbon
chain of vesicles, the information obtained from fluorescence of pyrene in our systems
refers to the bilayer of the vesicle pigeon-hole [18]. Pyrene may form intramolecular ex-
cimers. The process depends on the rate of conformational change of the molecule which
is sensitive to the viscosity of the probe microenvironment [19]. Hence the IE/IM ratio,
where IM and IE stand for the intensity of the monomer and the excimer fluorescence,
respectively, is used to estimate the microviscosity. Because of its high hydrophobicity,
the solubilization zone of pyrene is in the vesicle bilayer, as was established in the case
of polymeric micellar solutions [20]. The pyrene probe may also evidence (only qualita-
tively) the micropolarity variation in the solubilization region, by the change in the ratio
of monomer vibronic bands intensities measured at 377 nm and 397 nm [21].
3. – Results and discussion
The measurements carried out by DLS indicate that selected surfactants in presence
of Chol form vesicular structures with no significant different dh, while differences in
ζ-potential (table II) are evident between Sp20 and Tw20 empty vesicles. The higher
(in absolute value) ζ-potential of Sp20 vesicles is probably due to the absence of PEG
external coating. ζ-potential values allow to foresee the stability of the prepared formu-
lations. A high negative value of ζ-potential is important in preventing aggregation. It
has been reported that a physically stable nanosuspension solely stabilized by electro-
static repulsion will have a minimum ζ-potential of −30mV [22]. hMNPs Chemicell and
Colorobbia have dimensions of 50 nm and 20 nm, respectively, while lMNPs have dimen-
sions of 30 nm. There is not a significant increase/decrease of vesicular dimensions after
entrapment of MNPs. In particular Tw20 vesicles, hydrated with solutions of hMNPs
that are probably placed inside vesicular aqueous core, show unchanged dimensions com-














































































Fig. 1. – Physical stability of hMNPs entrapped in surfactant vesicle (samples A1 and A2).
Vesicle hydrodynamic diameter (dh) and ζ-potential values were evaluated by DLS at definite
time intervals (1, 30, 60, 90 days) at 25 ◦C (panel A) and 4 ◦C (panel B). Reported data are the
means of three experiments ± SD.
pared to empty ones, while in Sp20 vesicles the insertion of lMNPs in surfactant bilayer
is responsible of a slight increase in vesicle dimension. Only in the case of Chemicell
MNPs loaded Tw20 vesicles there is a decrease in ζ-potential values; the MNPs could
be placed also on the vesicle surface, inside the PEG coating, eliciting a variation in
ζ-potential values respect empty vesicles. Apart from providing dh and ζ-potential val-
ues, DLS provides also valuable information on the homogeneity of the suspension. A
single sharp peak in the DLS profile implies the existence of a single population of scat-
tering particles. DLS and PDI measurements indicated that the empty vesicles showed
a significant yield of homogeneous vesicular structures. The physical stability studies
of empty NSVs are widely reported in literature [23, 24]. From the analysis of obtained
results it is evident that Tw20 vesicles hydrated by hMNPs both of Colorobbia and of
Chemicell in 10mM Hepes buffer pH 7.4 are stable for at least 3 months when stored at
4 ◦C and at 25 ◦C (fig. 1 A and B). The same results have been obtained in the case of
Sp20 vesicles prepared in presence of lMNPs. Even ζ-potential values remain constant


























Fig. 2. – Physical stability of sample B1. Vesicle hydrodynamic diameter (dh) and ζ-potential
values were evaluated by DLS at definite time intervals (1, 30, 60, 90 days) at 25 ◦C and 4 ◦C.
Reported data are the means of three experiments ± SD.
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Table III. – Vesicle bilayer polarity (I1/I3) and microviscosity (IE/IM), evaluated by fluores-
cence studies.






The e.e. data (table II) show a good capability of the two type of vesicle of entrap
both hydrophilic and lipophilic MNPs. It is evident that the hMNPs are better entrapped
than the lMNPs ones probably due to the higher volume occupied by the aqueous core
respect to the the lipophilic bilayer. To better evaluate the influence of MNPs entrap-
ment on vesicle bilayer, fluorescence analyses were performed in order to evaluate bilayer
polarity and microviscosity (table III). The MNPs encapsulation led to different be-
haviour in vesicle bilayer respect to empty vesicles; the IE/IM values are rather constant
in the case of Tw20 vesicles-hMNPs Chemicell and Tw20 empty vesicles. This could be
related to a non-insertion of hydrophilic MNPs in vesicular bilayer, but in the case of
Colorobbia MNPs a slight, not significant variation is present. The unchanged values of
the microviscosity parameter confirm the location of hydrophilic MNPs in vesicular aque-
ous core. lMNPs loaded Sp20 vesicles show an increase in polarity and microviscosity
values with respect the empty vesicles, showing a more hydrophilic and viscous pyrene
microenvironment. This fact could be explained by the presence of the lMNPs inside
the bilayer which permits a partial water penetration, leading to an increase in polarity
and in microviscosity. The insertion of lMNPs in the bilayer could be responsible of the
slight increase of vesicle dimensions (table II). The low e.e., also with increasing lMNPs
loading amount, could be related to an excess of MNPs inside the bilayer, in some cases
leading to the inhibition of vesicular structure formation.
The reported results are very encouraging and confirm that Tw20 and Sp20 vesi-
cles could be promising carriers for the delivery of hydrophilic and lipophilic MNPs,
respectively, thereby prompting various opportunities for the development of suitable
theranostic therapeutic strategies. The analyzed formulations confirm the importance of
surfactant chemical-physical characteristics in entrapping the MNPs of different polarity,
highlighting the high versatility of niosomal bilayer and structure; property that make
them so appealing among drug delivery nanocarriers. In the future it could be very in-
teresting to deepen chemical-physical characterization of these structures together with
their magnetic properties analyses and try to entrap a model drug in these structures to
evaluate their theranostic potentiality.
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